Cargando…

Potential prognosis index for m(6)A-related mRNA in cholangiocarcinoma

BACKGROUND: Cholangiocarcinoma (CHOL) is a malignant tumor that originates in the extrahepatic bile duct and can extend from the hilar region to the lower end of the common bile duct. The prognosis of CHOL patients is particularly poor; therefore, in this study, we screened mRNAs correlated with N6-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Huaqiang, Zhao, Haini, Wang, Jianlu, Zhao, Shuchao, Ma, Chaoqun, Wang, Dongliang, Gao, Hengjun, Yang, Faji, Ni, Qingqiang, Li, Hongguang, Zhou, Xu, Zhang, Chunqing, Lu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170563/
https://www.ncbi.nlm.nih.gov/pubmed/35672673
http://dx.doi.org/10.1186/s12885-022-09665-3
_version_ 1784721457841963008
author Zhu, Huaqiang
Zhao, Haini
Wang, Jianlu
Zhao, Shuchao
Ma, Chaoqun
Wang, Dongliang
Gao, Hengjun
Yang, Faji
Ni, Qingqiang
Li, Hongguang
Zhou, Xu
Zhang, Chunqing
Lu, Jun
author_facet Zhu, Huaqiang
Zhao, Haini
Wang, Jianlu
Zhao, Shuchao
Ma, Chaoqun
Wang, Dongliang
Gao, Hengjun
Yang, Faji
Ni, Qingqiang
Li, Hongguang
Zhou, Xu
Zhang, Chunqing
Lu, Jun
author_sort Zhu, Huaqiang
collection PubMed
description BACKGROUND: Cholangiocarcinoma (CHOL) is a malignant tumor that originates in the extrahepatic bile duct and can extend from the hilar region to the lower end of the common bile duct. The prognosis of CHOL patients is particularly poor; therefore, in this study, we screened mRNAs correlated with N6-methyladenosine (m(6)A) to construct a risk model for prognosis in CHOL. METHODS: The TCGA-CHOL dataset was applied to obtain and analyze the coexpression of 1281 m(6)A-related mRNAs, from which 14 were selected for further analysis through univariate proportional hazards (cox) regression analysis. Aryl hydrocarbon receptor interacting protein (AIP), CCAAT/enhancer binding protein beta (CEBPB), syndecan1 (SDC1), vacuolar protein sorting 25 homolog (VPS25) and syntaxin binding protein 2 (STXBP2) were then screened out through the least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis to develop a precise m(6)A-related mRNA prognosis risk model (MRMRPM) with an area under curve (AUC) of 0.908 and 0.923 after 1 and 2 years, respectively. We divided the samples into high-risk and low-risk groups using the m(6)A-related mRNA prognosis risk model. RESULTS: Kaplan–Meier analysis indicated poor overall survival (OS) for the high-risk group. Two Gene Expression Omnibus (GEO) datasets (GSE89748 and GSE107943) were used to validate the risk model. The results of drug sensitivity and immune cell infiltration analysis showed that the risk model could serve as a prognosis index of potential immunotherapeutic characteristics and drug sensitivity. Furthermore, the proportion of resting dendritic cells and regulatory T cells was positively associated with an increased expression of four m(6)A-related mRNAs — AIP, CEBPB, SDC1, and VPS25 — in the high-risk CHOL group. CONCLUSIONS: Our findings suggest that this model can be a prognostic indicator for CHOL patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09665-3.
format Online
Article
Text
id pubmed-9170563
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91705632022-06-08 Potential prognosis index for m(6)A-related mRNA in cholangiocarcinoma Zhu, Huaqiang Zhao, Haini Wang, Jianlu Zhao, Shuchao Ma, Chaoqun Wang, Dongliang Gao, Hengjun Yang, Faji Ni, Qingqiang Li, Hongguang Zhou, Xu Zhang, Chunqing Lu, Jun BMC Cancer Research BACKGROUND: Cholangiocarcinoma (CHOL) is a malignant tumor that originates in the extrahepatic bile duct and can extend from the hilar region to the lower end of the common bile duct. The prognosis of CHOL patients is particularly poor; therefore, in this study, we screened mRNAs correlated with N6-methyladenosine (m(6)A) to construct a risk model for prognosis in CHOL. METHODS: The TCGA-CHOL dataset was applied to obtain and analyze the coexpression of 1281 m(6)A-related mRNAs, from which 14 were selected for further analysis through univariate proportional hazards (cox) regression analysis. Aryl hydrocarbon receptor interacting protein (AIP), CCAAT/enhancer binding protein beta (CEBPB), syndecan1 (SDC1), vacuolar protein sorting 25 homolog (VPS25) and syntaxin binding protein 2 (STXBP2) were then screened out through the least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis to develop a precise m(6)A-related mRNA prognosis risk model (MRMRPM) with an area under curve (AUC) of 0.908 and 0.923 after 1 and 2 years, respectively. We divided the samples into high-risk and low-risk groups using the m(6)A-related mRNA prognosis risk model. RESULTS: Kaplan–Meier analysis indicated poor overall survival (OS) for the high-risk group. Two Gene Expression Omnibus (GEO) datasets (GSE89748 and GSE107943) were used to validate the risk model. The results of drug sensitivity and immune cell infiltration analysis showed that the risk model could serve as a prognosis index of potential immunotherapeutic characteristics and drug sensitivity. Furthermore, the proportion of resting dendritic cells and regulatory T cells was positively associated with an increased expression of four m(6)A-related mRNAs — AIP, CEBPB, SDC1, and VPS25 — in the high-risk CHOL group. CONCLUSIONS: Our findings suggest that this model can be a prognostic indicator for CHOL patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09665-3. BioMed Central 2022-06-07 /pmc/articles/PMC9170563/ /pubmed/35672673 http://dx.doi.org/10.1186/s12885-022-09665-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhu, Huaqiang
Zhao, Haini
Wang, Jianlu
Zhao, Shuchao
Ma, Chaoqun
Wang, Dongliang
Gao, Hengjun
Yang, Faji
Ni, Qingqiang
Li, Hongguang
Zhou, Xu
Zhang, Chunqing
Lu, Jun
Potential prognosis index for m(6)A-related mRNA in cholangiocarcinoma
title Potential prognosis index for m(6)A-related mRNA in cholangiocarcinoma
title_full Potential prognosis index for m(6)A-related mRNA in cholangiocarcinoma
title_fullStr Potential prognosis index for m(6)A-related mRNA in cholangiocarcinoma
title_full_unstemmed Potential prognosis index for m(6)A-related mRNA in cholangiocarcinoma
title_short Potential prognosis index for m(6)A-related mRNA in cholangiocarcinoma
title_sort potential prognosis index for m(6)a-related mrna in cholangiocarcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170563/
https://www.ncbi.nlm.nih.gov/pubmed/35672673
http://dx.doi.org/10.1186/s12885-022-09665-3
work_keys_str_mv AT zhuhuaqiang potentialprognosisindexform6arelatedmrnaincholangiocarcinoma
AT zhaohaini potentialprognosisindexform6arelatedmrnaincholangiocarcinoma
AT wangjianlu potentialprognosisindexform6arelatedmrnaincholangiocarcinoma
AT zhaoshuchao potentialprognosisindexform6arelatedmrnaincholangiocarcinoma
AT machaoqun potentialprognosisindexform6arelatedmrnaincholangiocarcinoma
AT wangdongliang potentialprognosisindexform6arelatedmrnaincholangiocarcinoma
AT gaohengjun potentialprognosisindexform6arelatedmrnaincholangiocarcinoma
AT yangfaji potentialprognosisindexform6arelatedmrnaincholangiocarcinoma
AT niqingqiang potentialprognosisindexform6arelatedmrnaincholangiocarcinoma
AT lihongguang potentialprognosisindexform6arelatedmrnaincholangiocarcinoma
AT zhouxu potentialprognosisindexform6arelatedmrnaincholangiocarcinoma
AT zhangchunqing potentialprognosisindexform6arelatedmrnaincholangiocarcinoma
AT lujun potentialprognosisindexform6arelatedmrnaincholangiocarcinoma